• Home
  • NEW DAY MEDICINE
  • 9 (59) 2023
  • 4 -9 (59) 2023 — Suleimanova S.S., Sulima D.L. — SUCCESSFUL ANTIVIRAL THERAPY FOR CHRONIC HGV- INFECTION IN A PATIENT WITH CLINICALLY SIGNIFICANT CRYOFIBRINOGENEMIA

4 -9 (59) 2023 — Suleimanova S.S., Sulima D.L. — SUCCESSFUL ANTIVIRAL THERAPY FOR CHRONIC HGV- INFECTION IN A PATIENT WITH CLINICALLY SIGNIFICANT CRYOFIBRINOGENEMIA

SUCCESSFUL ANTIVIRAL THERAPY FOR CHRONIC HGV- INFECTION IN A PATIENT WITH CLINICALLY SIGNIFICANT CRYOFIBRINOGENEMIA

Suleimanova S.S., LLC MCDC “Exclusive”(Medical Clinic EXCLUSIVE) / Specialized Department of Innovative Hepatology; Russian Federation

Sulima D.L., LLC MCDC “Exclusive”(Medical Clinic EXCLUSIVE) / Specialized Department of Innovative Hepatology; Russian Federation

Rassokhin V.V., FBIS “STP RIEAM named after Pasteur”/ Laboratory of immunology and virology of HIV- infection; Russian Federation

Lapin S.V. FSBEIHE “TFTPSMU named after acad. I.P. Pavlov”/ Laboratory for diagnosis of autoimmune diseases; Russian Federation

Resume

Introduction. Previously, there were no publications in the Russian Federation about chronic HGV-infection combined with cryofibrinogenemia.

Сase report. The authors described a case of cryofibrinogenemia, clinically manifested by retinal vascular microtrombosis in a patient with HCV-HGV coinfection that persist after successful HCV eradication. After the off-label use PegIFN-a-2a therapy and the disappearance of HGV RNA from plasma and PBMCs, the patient showed clinical and laboratory improvement.

Discussion/conclusion. For the first time in Russia, a clinical case of a combination of chronic HGV RNA viremia and cryofibrinogenemia has been described and a successful course of antiviral therapy with PegIFN-a-2a has been conducted.

Keywords: case report, cryofibrinogenemia, direct-acting antiviral agents, GBV-C, HCV/HGV coinfection, HPgV-2, PegIFN-a-2a

First page

18

Last page

24

For citation: Suleimanova S.S., Sulima D.L., Rassokhin V.V., Lapin S.V. – SUCCESSFUL ANTIVIRAL THERAPY FOR CHRONIC HGV- INFECTION IN A PATIENT WITH CLINICALLY SIGNIFICANT CRYOFIBRINOGENEMIA //New Day in Medicien 2023 9(59): 18-24 https://newdaymedicine.com/index.php/2023/09/05/l-342/

LIST OF REFERENCES:

  1. H. Hofer, I. Aydin, S. Neumueller‐Guber et al. Prevalence and clinical significance of GB virus type C/hepatitis G virus coinfection in patients with chronic hepatitis C undergoing antiviral therapy // Journal of Viral Hepatitis. 2010;18(7):513–517. doi:10.1111/j.1365-2893.2010.01340.x. 
  2. Mark D.Berzsenyi, D. Scott Bowden, Stuart K.Roberts. GB virus C: Insights into co-infection // Journal of Clinical Virology. 2005;33(4):257-266. doi: 10.1016/j.jcv.2005.04.002.
  3. Zhengwei Wan,Junwei Liu,Fengyu Hu et al. Evidence that the second human pegivirus (HPgV-2) is primarily a lymphotropic virus and can replicate independent of HCV replication // Emerg Microbes Infect. 2020;9(1):485–495. doi: 10.1080/22221751.2020.1730247.
  4. Angelo Fama,  Melissa C Larson, Brian K Linket al. Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis // Clin Infect Dis. 2020;71(5):1221-1228. doi: 10.1093/cid/ciz940.
  5. X Fan, Y Xu, H Solomon et al. Is hepatitis G/GB virus-C virus hepatotropic? Detection of hepatitis G/GB virus-C viral RNA in liver and serum // J Med Virol. 1999;58(2):160–4 . PMID: 10335864.
  6. Reshetnyak V., Karlovich T., Ilchenko L. Hepatitis G virus // World J Gastroenterol. 2008; 14(30):4725–4734. doi: 10.3748/wjg.14.4725.
  7. H. L. Tillmann, M. P. Manns , C. Claes et al. GB virus C infection and quality of life in HIV-positive patients // AIDS Care. 2010;16(6):736-743. doi: 10.1080/09540120412331269576.
  8. Sarah L. George, Dino Varmaz, John E. Tavis. The GB Virus C (GBV-C) NS3 Serine Protease Inhibits HIV-1 Replication in a CD4+ T Lymphocyte Cell Line without Decreasing HIV Receptor Expression // PLoS ONE. 2012;7(1). doi: 10.1371/journal.pone.0030653.
  9. Nirjal Bhattarai, Jack T Stapleton. GB virus C: the good boy virus? // Trends Microbiol. 2012;20(3):124-30. doi: 10.1016/j.tim.2012.01.004.
  10. K Abe. GB virus-C/hepatitis G virus // Jpn J Infect Dis. 2001 Apr;54(2):55-63. PMID: 11427742
  11. T J Tucker,  H E Smuts, C Eedes et al. Evidence that the GBV-C/hepatitis G virus is primarily a lymphotropic virus // J Med Virol. 2000;61(1):52–8. PMID: 12749244.
  12. David Saadoun, Ismail Elalamy, Pascale Ghillani-Dalbin et al. Cryofibrinogenemia: New insights into clinical and pathogenic features // Am I Med. 2009 Dec; 122(12):1128-35. doi: 10.1016/j.amjmed.2009.03.040.
  13. Martin Michaud, Guillaume Moulis, Benedicte Puissant  et al. Cryofibrinogenemia: a marker of severity of cryoglobulinemic vasculitis // Am J Med. Aug 2015;128(8):916-21. doi: 10.1016/j.amjmed.2015.03.009.
  14. L M Jarvis, H Bell, P Simmonds et al. The effect of treatment with alpha-interferon on hepatitis G/GBV-C viraemia // Scand J Gastroenterol. Feb1998;33(2):195-200. doi: 10.1080/00365529850166941.
  15. Lau JY, et al. Effect of interferon-alpha and ribavirin therapy on serum GB virus C/hepatitis G virus (GBV-C/HGV) RNA levels in patients chronically infected with hepatitis C virus and GBV-C/HGV // J Infect Dis. 1997;176(2):421-6. doi: 10.1086/514059.

file

download